• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用重组蛋白和合成肽定位风疹病毒结构蛋白的细胞介导免疫显性区域。

Mapping cell-mediated immunodominant domains of the rubella virus structural proteins using recombinant proteins and synthetic peptides.

作者信息

Lovett A E, McCarthy M, Wolinsky J S

机构信息

University of Texas Health Science Center, Department of Neurology, Houston 77030.

出版信息

J Gen Virol. 1993 Mar;74 ( Pt 3):445-52. doi: 10.1099/0022-1317-74-3-445.

DOI:10.1099/0022-1317-74-3-445
PMID:8445367
Abstract

Although it is known that rubella-immune individuals have T cells that proliferate in vitro in response to rubella virus (RV), the determinants that evoke this response have not been identified. This study utilized recombinant proteins that express overlapping sequences of the RV structural open reading frame to identify domains of the structural proteins that contain cell-mediated immunodominant sequences. Lysates enriched with RV fusion proteins (RecA-RV-LacZ) were prepared from Escherichia coli transformed with plasmids which contained specific RV cDNA inserts. Approximately 62% of RV-immune individuals gave RV-specific responses to one or more of the RV fusion proteins. Over 10% of immune individuals recognized the capsid sequence C1-C29. Lymphoproliferation data from studies using six overlapping synthetic peptides representing this sequence suggested that as much as 70% of the immune population may recognize this domain. An E1 sequence, E1(202)-E1(283), was recognized by 15% of the RV-immune individuals with the fusion proteins. Five synthetic peptides representing this sequence had an overall response rate of 50%. The sequence C64-C97 failed to evoke any RV-specific responses with the fusion proteins and synthetic peptides representing this sequence were used to verify that the RV fusion proteins and the criteria used to identify RV-specific responses were adequate. These peptides gave a response rate of only 6%. In general, significant responses to specific fusion proteins correlated with high responses (stimulation index > or = 4.0) to representative synthetic peptides. This study suggests that the recombinant proteins were beneficial in identifying cell-mediated immunodominant domains of the RV structural proteins which could be further characterized with synthetic peptides.

摘要

尽管已知风疹免疫个体具有可在体外对风疹病毒(RV)产生增殖反应的T细胞,但引发这种反应的决定因素尚未确定。本研究利用表达RV结构开放阅读框重叠序列的重组蛋白,来鉴定结构蛋白中包含细胞介导免疫显性序列的结构域。从用含有特定RV cDNA插入片段的质粒转化的大肠杆菌中制备富含RV融合蛋白(RecA-RV-LacZ)的裂解物。约62%的风疹免疫个体对一种或多种RV融合蛋白产生风疹特异性反应。超过10%的免疫个体识别衣壳序列C1-C29。使用代表该序列的六种重叠合成肽进行研究所得的淋巴细胞增殖数据表明,多达70%的免疫人群可能识别该结构域。15%的风疹免疫个体在用融合蛋白检测时识别E1序列E1(202)-E1(283)。代表该序列的五种合成肽的总体反应率为50%。序列C64-C97在用融合蛋白检测时未引发任何风疹特异性反应,并且使用代表该序列的合成肽来验证RV融合蛋白及用于鉴定风疹特异性反应的标准是合适的。这些肽的反应率仅为6%。一般来说,对特定融合蛋白的显著反应与对代表性合成肽的高反应(刺激指数≥4.0)相关。本研究表明,重组蛋白有助于鉴定RV结构蛋白的细胞介导免疫显性结构域,这些结构域可用合成肽作进一步表征。

相似文献

1
Mapping cell-mediated immunodominant domains of the rubella virus structural proteins using recombinant proteins and synthetic peptides.利用重组蛋白和合成肽定位风疹病毒结构蛋白的细胞介导免疫显性区域。
J Gen Virol. 1993 Mar;74 ( Pt 3):445-52. doi: 10.1099/0022-1317-74-3-445.
2
Immunodominant T-cell epitopes of rubella virus structural proteins defined by synthetic peptides.由合成肽确定的风疹病毒结构蛋白的免疫显性T细胞表位
J Virol. 1993 Feb;67(2):673-81. doi: 10.1128/JVI.67.2.673-681.1993.
3
Mapping T-cell epitopes of rubella virus structural proteins E1, E2, and C recognized by T-cell lines and clones derived from infected and immunized populations.绘制风疹病毒结构蛋白E1、E2和C的T细胞表位图谱,该表位由来自感染和免疫人群的T细胞系及克隆所识别。
J Med Virol. 1993 Jul;40(3):175-83. doi: 10.1002/jmv.1890400302.
4
Monoclonal antibody-defined epitope map of expressed rubella virus protein domains.风疹病毒表达蛋白结构域的单克隆抗体界定表位图谱
J Virol. 1991 Aug;65(8):3986-94. doi: 10.1128/JVI.65.8.3986-3994.1991.
5
Identification of immunoreactive regions of rubella virus E1 and E2 envelope proteins by using synthetic peptides.利用合成肽鉴定风疹病毒E1和E2包膜蛋白的免疫反应区
Virus Res. 1993 Jul;29(1):33-57. doi: 10.1016/0168-1702(93)90124-6.
6
Rubella virus-specific cytotoxic T-lymphocyte responses: identification of the capsid as a target of major histocompatibility complex class I-restricted lysis and definition of two epitopes.风疹病毒特异性细胞毒性T淋巴细胞反应:衣壳作为主要组织相容性复合体I类限制性裂解靶点的鉴定及两个表位的定义。
J Virol. 1993 Oct;67(10):5849-58. doi: 10.1128/JVI.67.10.5849-5858.1993.
7
An antibody- and synthetic peptide-defined rubella virus E1 glycoprotein neutralization domain.一个由抗体和合成肽定义的风疹病毒E1糖蛋白中和结构域。
J Virol. 1993 Feb;67(2):961-8. doi: 10.1128/JVI.67.2.961-968.1993.
8
Immunogenicity study of a synthetic T-cell epitope of rubella virus capsid protein recognized by human T cells in different strains of mice.
Viral Immunol. 1994;7(1):41-5. doi: 10.1089/vim.1994.7.41.
9
Use of synthetic peptides to map regions of rubella virus capsid protein recognized by human T lymphocytes.使用合成肽来绘制风疹病毒衣壳蛋白中被人T淋巴细胞识别的区域。
Vaccine. 1994 May;12(7):639-45. doi: 10.1016/0264-410x(94)90270-4.
10
Human T- and B-cell epitopes of E1 glycoprotein of rubella virus.风疹病毒E1糖蛋白的人T细胞和B细胞表位
J Clin Immunol. 1993 Mar;13(2):93-100. doi: 10.1007/BF00919265.

引用本文的文献

1
Lymphoproliferative responses after infection with human parvovirus B19.人细小病毒B19感染后的淋巴细胞增殖反应。
J Virol. 1996 Oct;70(10):7327-30. doi: 10.1128/JVI.70.10.7327-7330.1996.
2
Expression and characterization of virus-like particles containing rubella virus structural proteins.含有风疹病毒结构蛋白的病毒样颗粒的表达与特性分析
J Virol. 1994 Jun;68(6):4086-91. doi: 10.1128/JVI.68.6.4086-4091.1994.
3
Rubella virus-specific cytotoxic T-lymphocyte responses: identification of the capsid as a target of major histocompatibility complex class I-restricted lysis and definition of two epitopes.
风疹病毒特异性细胞毒性T淋巴细胞反应:衣壳作为主要组织相容性复合体I类限制性裂解靶点的鉴定及两个表位的定义。
J Virol. 1993 Oct;67(10):5849-58. doi: 10.1128/JVI.67.10.5849-5858.1993.